Trials / Completed
CompletedNCT03164291
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- The University of Texas Health Science Center at Tyler · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.
Detailed description
Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifabutin | Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status |
Timeline
- Start date
- 1984-06-01
- Primary completion
- 2006-09-01
- Completion
- 2017-05-18
- First posted
- 2017-05-23
- Last updated
- 2017-05-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03164291. Inclusion in this directory is not an endorsement.